Orbit Discovery and start-up SanegeneBio have entered into a Master Service Agreement to identify tissue-specific delivery of a wide range of RNA therapeutics.
The agreement covers activities ranging from hit ID to cell-based internalisation studies, with an option for Sanegene to further develop the hits resulting from the screening activities.
Orbit’s technology enables the screening of large libraries of peptides using a combination of DNA encoded libraries and bead-based presentation. The peptide display engine addresses soluble targets and targets in situ, both on and in cells.
Dr Neil Butt, Chief Executive Officer of Orbit Discovery, commented: “Sanegene has established an incredible ability to screen for RNAi molecules in a robust and efficient manner.
“Our aim is to make screening more relevant to the final biological read-outs, to ensure the right leads are selected first time, every time. This has the end goal of enabling the generation of future therapeutics with low toxicity and tissue specificity and ultimately, safer and more effective medicines.”